Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Jan;18(1):5-7.
doi: 10.5214/ans.0972.7531.1118103.

Prognostic significance of ischemia-modified albumin in acute ischemic stroke patients: A preliminary study

Amit R Nayak  1 , Rajpal S Kashyap  1 , Dinesh Kabra  1 , Hemant J Purohit  2 , Girdhar M Taori  1 , Hatim F Daginawala  1
Affiliations

Prognostic significance of ischemia-modified albumin in acute ischemic stroke patients: A preliminary study

Amit R Nayak et al. Ann Neurosci. 2011 Jan.

Abstract

Background: Ischemia-modified albumin (IMA) is a sensitive marker of ischemic event. However, limited studies are available regarding role of IMA in acute ischemic stroke (AIS).

Purpose: The aim of this study was to evaluate time course of IMA in AIS patient to validate its prognostic value.

Methods: IMA level was estimated in serum samples collected from five AIS patients at admission, 24hrs, 48hrs, 72hrs, and 144hrs after admission and also from five control subjects.

Results: There was significant (p<0.05) increase in IMA level in AIS samples at admission, 24hrs, 48hrs and 144hrs respectively when compared with control. On comparing IMA levels in follow up AIS samples with that of admission value we found that it decreased in follow-up samples till 72hrs, and significant (p<0.05) decrease was observed at 24hrs and 72hrs.

Conclusion: Findings shows that follow up estimation of IMA level in AIS may help in the prediction of the clinical status and outcome.

Keywords: Acute ischemic stroke; Biomarker; Ischemia modified albumin; Prognosis; Serum marker.

PubMed Disclaimer

Conflict of interest statement

Competing interests – None

Figures

Fig. 1:
Fig. 1:
Distribution of the IMA in serum samples from control group (n =5) and follow-up samples of AIS patients (n =5)
Fig. 2:
Fig. 2:
IMA level in control group (n =5) and AIS patients (n =5). *p - value <0.05, control vs. 0hrs, 24hrs, 48hrs, and 144hrs similarly ap - value <0.05 Admission (0hrs) vs. 24hrs, 48hrs, 72hrs 144hrs respectively
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Banerjee TK, Das SK. Epidemiology of stroke in India. Neurology Asia. 2006;11:1–4.
    1. Stringer KA. Clinical trials in thrombolytic therapy, Part 1: Outcome markers that go beyond mortality reduction. Am J Health Syst Pharm. 1997;54(1):S23–S26. - PubMed
    1. Kashyap RS, Kabra DP, Nayak AR et al. Protein electrophoretogram in serum of acute ischemic stroke patients and its correlation with S-100β and neuron specific enolase level: A pilot study. Annals of Neurosciences. 2006;13(2):36–40.
    1. Cuzzocrea S, Riley DP, Caputi AP et al. Antioxidant therapy: a new pharmacological approach in shock, inflammation, and ischemia/reperfusion injury. Pharmacol Rev. 2001;53:135–159. - PubMed
    1. Roy D, Quiles J, Gaze DC et al. Role of reactive oxygen species on the formation of the novel diagnostic marker ischaemia modified albumin. Heart. 2006;92(1):113–114. - PMC - PubMed

LinkOut - more resources